Clinical trials: Hepatocellular Carcinoma
Breast Cancer, Lung Cancer
Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
To characterize the safety and tolerability of NIS793 as single agent and in combination with PDR001 and to identify recommended doses for future studies.
- Conditions
- Breast Cancer, Lung Cancer, Hepatocellular Cancer, Colorectal Cancer
- Trial name
- NCT02947165
- Testing
- NIS793, PDR001
- Where
- 12 sites in United States, Austria and 7 more
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Hepatocellular Carcinoma
Open-label Multicenter Phase 1 Study of TBI 302 as Second-Line Therapy in Patients With Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. TBI 302 is being developed for the treatment of inoperable HCC by intravenous infusion.
- Trial name
- NCT03908840
- Testing
- TBI 302
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Evolve Biologics
Hepatocellular Carcinoma
RFA Combined With Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) for Recurrent HCC
Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world. Partial hepatectomy and liver transplantation are considered to be standard curative therapies for HCC.
- Trial name
- NCT02426450
- Testing
- RFA, Oxaliplatin, 5-Fluorouracil/Leucovorin
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma, Adjuvant Therapy
Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma
This study aims to evaluate the efficacy and safety of donafenib as adjuvant therapy for postoperative patients with high-risk recurrent Hepatocellular Carcinoma. This is a multicenter, randomized controlled study.
- Trial name
- NCT06581315
- Testing
- Donafenib
- Where
- China
- Volunteers
- 204 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Hepatocellular Carcinoma (HCC) Prognosis, Contrast-enhanced Ultrasound
A Comparative Study on the Diagnostic Efficacy of Ultrasound Contrast LI-RADS Grading and the German ESCULAP Standards for the Diagnosis of Recurrent Hepatic Mass Lesions After Hepatocellular Carcinoma Surgery
Hepatocellular carcinoma (HCC) is the sixth most common malignant tumor worldwide, with a significantly increased incidence among patients with liver diseases.
- Trial name
- NCT07600346
- Testing
- Contrast-Enhanced Ultrasound
- Volunteers
- 105 people
- Sponsor
- The First Hospital of Jilin University
Hepatocellular Carcinoma
Phenotyping Liver Cancer Registry
The purpose of this study is the development of a content-based image retrieval (CBIR) platform, where validation studies will be conducted for liver disease subtyping and hepatocellular carcinoma (HCC) phenotyping on images for…
- Trial name
- PHELICAR (NCT04681274)
- Testing
- Image features extraction and clustering, Phenotype signature database building
- Where
- France
- Volunteers
- 2,429 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatocellular Carcinoma
Bipolar RFA Using Twin ICW Electrodes vs. Switching Monopolar RFA for Recurrent HCC
This study was conducted to provide preliminary data for the main trial to compare efficacy between bipolar radiofrequency ablation (RFA) using twin internally cooled-wet electrodes and switching monopolar RFA using separable…
- Trial name
- NCT03806218
- Testing
- Bipolar RFA, SM-RFA, Twin internally cooled-wet electrodes
- Where
- South Korea
- Volunteers
- 77 people
- Sponsor
- Seoul National University Hospital
Laparoscopic Hepatectomy, Hepatocellular Carcinoma
Surgical Specification and Efficacy Evaluation of Total Laparoscopic Left Liver Resection
Recent clinical experience showed that laparoscopic hepatectomy has advantages of minimally invasive compared to open liver resection, however, laparoscopic liver resection is still difficult and risky.
- Trial name
- NCT02131441
- Testing
- laparoscopic hepatectomy, open liver resection
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Solid Tumor Cancer, Adult Refractory Cancer
Study of GV20-0251 in Participants With Solid Tumor Malignancies
This is a Phase 1 and Phase 2 study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
- Conditions
- Solid Tumor Cancer, Adult Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma
- Trial name
- NCT07070518
- Testing
- GV20-0251
- Where
- 3 sites in China
- Volunteers
- 350 people
- Sponsor
- GV20 Therapeutics
Hepatocellular Carcinoma, Pulmonary Metastasis
Treatment Patients With Pulmonary Metastasis of Liver Cancer With Apatinib Combination With TACE: a Clinical Study
This study mainly evaluate the clinical effect of Apatinib in the treatment of patients with pulmonary metastasis of hepatocellular carcinoma.Half of participants will receive Apatinib and transcatheter arterial chemoembolization…
- Trial name
- NCT02702323
- Testing
- Apatinib, TACE
- Volunteers
- 40 people
- Sponsor
- Zhejiang Cancer Hospital
Hepatocellular Carcinoma
MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
This is an open-label, multicenter, Phase I/II clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of MRG006A in combination with immune checkpoint inhibitors and targeted…
- Trial name
- NCT07479485
- Testing
- MRG006A, Pucotenlimab, Bevacizumab
- Where
- 8 sites in China
- Volunteers
- 160 people
- Sponsor
- Lepu Biopharma Co., Ltd.
Cancer, Renal Cell Carcinoma (RCC)
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
The primary objective of this long-term extension study is to allow continued access to study treatment for eligible participants who are deriving clinical benefit in an Exelixis-sponsored study who do not have access to…
- Conditions
- Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET)
- Trial name
- NCT07620574
- Testing
- Cabozantinib, Zanzalintinib, Atezolizumab
- Where
- 4 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- Exelixis
Hepatocellular Carcinoma
Role of Positron Emission Tomography in the Evaluation of Response to Sorafenib in Advanced Hepatocellular Carcinoma
Positron emission tomography (PET) with [18F]fluorodeoxyglucose (FDG-PET) evaluates cancer cell glycolysis(Warburg effect) as a surrogate for tumor response.The hypothesis of this study is that early changes in FDG-PET signal can…
- Trial name
- NCT01157013
- Testing
- Positron emission tomography with fludeoxyglucose F 18
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Hospital Miguel Servet
HCC, Adjuvant Therapy
Sintilimab Plus Bevacizumab as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Curative Resection
This is an open label, multi-center, randomized, controlled phase III study, to evaluate the efficacy and safety of sintilimab plus bevacizumab as adjuvant therapy in hepatocellular carcinoma (HCC) patients who are at high risk…
- Conditions
- HCC, Adjuvant Therapy, Immunotherapy
- Trial name
- DaDaLi (NCT04682210)
- Testing
- Sintilimab, Bevacizumab
- Where
- China
- Volunteers
- 246 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma
This prospective, multicenter, phase II randomized controlled trial compares the efficacy and safety of SBRT combined with systemic therapy versus systemic therapy alone in BCLC stage C hepatocellular carcinoma (HCC).
- Trial name
- NCT07274774
- Testing
- Systemic therapy, Radiotherapy
- Where
- China
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- Shandong Cancer Hospital and Institute
Hepatocellular Carcinoma
HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC
To Evaluate the Efficacy and Safety of the Hepatic Arterial Infusion Chemotherapy(HAIC) Combined With Sintilimab and Bevacizumab Biosimilar in the Treatment of Patients With Unresectable Hepatocellular Carcinoma.
- Trial name
- NCT05029973
- Testing
- HAIC, Sintilimab, Bevacizumab Biosimilar
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Advanced/Metastatic Hepatocellular Carcinoma
IIT Study of M1-c6v1 Combined With SHR-1210 and Apatinib in Patients With HCC
This is a single arm and open-label phase I trial to evaluate the safety, tolerability and efficacy of the oncolytic virus M1 （M1-c6v1）(iv 1×109 CCIC50, 1 dose per day, on day 1-5 each 28 day cycle) combined with anti-PD-1…
- Trial name
- NCT04665362
- Testing
- Recombinant oncolytic virus M1, anti PD-1 antibody, Apatinib
- Volunteers
- 10 people
- Sponsor
- Liang Peng
Liver Tumor
Treat-and-resect Study of Echo Decorrelation Imaging-controlled Radiofrequency Ablation in Liver Tumors
This study will comprise the first pilot clinical trial of 3D, ultrasound-based thermal ablation control using echo decorrelation imaging, directly testing the capability of this approach to ensure reliable tumor treatment.
- Trial name
- NCT05211388
- Testing
- RFA controlled using echo decorrelation imaging, RFA controlled using standard manufacturer-specified algorithms
- Where
- United States
- Sponsor
- University of Cincinnati
Hepatocellular Carcinoma
LiverMultiScan Analysis of MRI Scans in HCC
This project is a pilot study to interrogate the potential of LMS as a predictive tool for the selection of therapy for HCC patients.
- Trial name
- NCT04451603
- Testing
- Surgery, Radiation therapy, Drug treatment
- Where
- Singapore
- Volunteers
- 21 people
- Sponsor
- National Cancer Centre, Singapore
Hepatocellular Carcinoma, Portal Vein Tumor Thrombosis
Safety and Efficacy of Radiotherapy Plus Sintilimab for HCC With Portal Vein Tumor Thrombosis
The proposed study is an open-label, single-center, single arm phase 1b study to evaluate the safety and efficacy of radiotherapy plus sintilimab for HCC with PVTT.
- Trial name
- NCT04104074
- Testing
- Radiotherapy, Sintilimab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital